WuXi AppTec Group and Mayo Clinic Receive 2018 MedTech Insight Award for Best Alliance

SHANGHAI and ROCHESTER, Minn. /PRNewswire/ -- WuXi AppTec Group and Mayo Clinic recently received the 2018 MedTech Insight Award for the Best Partnership/Alliance on the formation of WuXi Diagnostics, the joint venture between the two parties. The award was received on September 26 in Philadelphia at the MedTech Conference, a premier annual gathering for the medical technology industry.

The In Vivo Award for Best MedTech Partnership/Alliance honors two or more organizations whose joint activity sets a new benchmark in health care. The partnership could involve multiple medical technology companies or pharmaceutical firms, or it could include a medical technology company and a contract research organization, research institute, not-for-profit, or cooperative group.

WuXi Diagnostics is a strategic collaboration between WuXi AppTec Group and Mayo Clinic. The joint venture is developing an open-technology platform, which enables every scientist to commercialize innovative ideas into cutting-edge clinical tests for complex diseases. The company will build up a medical databank based on its two enabling platforms and educate health care providers across all levels of hospitals. WuXi Diagnostics will accelerate the development of esoteric tests that both organizations will offer in their respective markets with the intent to benefit not only patients in China but around the world. 

"We are pleased to receive this award. This joint venture is at a very early stage and is growing rapidly. Our vision is to ensure every disease can be precisely diagnosed," said Jason Liu, Ph.D., General Manager of WuXi Diagnostics. "With support from two great organizations -- WuXi AppTec Group and Mayo Clinic -- we are confident that WuXi Diagnostics will achieve its vision, enable doctors to make better diagnoses for their patients, elevate a hospital's disease-management program, and accelerate innovation for the clinical diagnostics industry. Together, we want to bring the best testing solutions from research to the clinical practice."

"Mayo Clinic is honored to receive this award from MedTech," said William Morice, II, M.D., Ph.D., President of Mayo Medical Laboratories and Chair of Laboratory Medicine and Pathology at Mayo Clinic. "WuXi AppTec Group has a deep understanding of the Chinese market, rich resources to support this joint venture, and the ability to execute. We are pleased to have this strong collaboration in China to accelerate diagnostic research into tests that will help patients all over the world."


About Mayo Medical Laboratories and the Department of Laboratory Medicine and Pathology
The Mayo Clinic Department of Laboratory Medicine and Pathology and its reference laboratory Mayo Medical Laboratories provide advanced laboratory testing and pathology services to support 4,000 health care organizations around the world. Revenue from this testing supports medical education and research at Mayo Clinic, a nonprofit worldwide leader in medical care, research and education for people from all walks of life. Complemented by collaborations with diagnostic and biotechnology companies, the department maintains a robust diagnostic test-development program, launching more than 100 new tests each year.

About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to clinical practice, education, and research, providing expert, comprehensive care to everyone who needs healing. For more information, visit mayoclinic.org/about-mayo-clinicor newsnetwork.mayoclinic.org.

About WuXi Diagnostics

WuXi Diagnostics is a joint venture formed in 2018 between WuXi AppTec Group and Mayo Clinic. The company mission is to build an innovative platform which enables both esoteric testing service and in-vitro diagnostic (IVD) product innovation, integrates multi-dimensional data, generates clinical insights, benefits health of mankind through precision medicine, and ultimately fulfills the vision of "every disease can be precisely diagnosed."

 

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

Q: